Tekla Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Tekla Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-533,000	Closed	-$12.8M	–	162
2017 Q2	$12.8M	Sell	533,000 -229,581	-30%	-$5.08M	0.48%	50
2017 Q1	$14.7M	Hold	762,581	–	–	0.57%	38
2016 Q4	$11.7M	Hold	762,581	–	–	0.5%	47
2016 Q3	$9.92M	Hold	762,581	–	–	0.38%	60
2016 Q2	$10.6M	Hold	762,581	–	–	0.43%	58
2016 Q1	$11.6M	Hold	762,581	–	–	0.49%	51
2015 Q4	$14.5M	Hold	762,581	–	–	0.52%	40
2015 Q3	$14.5M	Buy	762,581 +71,581	+10%	+$1.78M	0.52%	40
2015 Q2	$17.8M	Buy	+691,000	New	+$19.6M	0.64%	34

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Tekla Capital Management's PRTK Position: Q3 2017 in Review

Tekla Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 533,000 shares — an estimated $12.8M sold.

Tekla Capital Management first reported a position in PRTK in Q2 2015 and held it in 9 quarters. The position peaked at $17.8M in Q2 2015. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

Tekla Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Tekla Capital Management sold 533,000 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $12.8M.
Tekla Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 9 quarters.
Tekla Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $17.8M in Q2 2015.
133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.